These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 11189513

  • 1. [In vitro study on arsenic trioxide-induced apoptosis of retinoic acid resistant acute promyelocytic leukemia cell line(MR-2)].
    Cai X, Jia P, Shi X.
    Zhonghua Xue Ye Xue Za Zhi; 1998 Jul; 19(7):339-41. PubMed ID: 11189513
    [Abstract] [Full Text] [Related]

  • 2. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells.
    Shao W, Fanelli M, Ferrara FF, Riccioni R, Rosenauer A, Davison K, Lamph WW, Waxman S, Pelicci PG, Lo Coco F, Avvisati G, Testa U, Peschle C, Gambacorti-Passerini C, Nervi C, Miller WH.
    J Natl Cancer Inst; 1998 Jan 21; 90(2):124-33. PubMed ID: 9450572
    [Abstract] [Full Text] [Related]

  • 3. Arsenic trioxide (As2O3)-induced apoptosis and differentiation in retinoic acid-resistant acute promyelocytic leukemia model in hGM-CSF-producing transgenic SCID mice.
    Kinjo K, Kizaki M, Muto A, Fukuchi Y, Umezawa A, Yamato K, Nishihara T, Hata J, Ito M, Ueyama Y, Ikeda Y.
    Leukemia; 2000 Mar 21; 14(3):431-8. PubMed ID: 10720138
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia.
    Cai X, Shen YL, Zhu Q, Jia PM, Yu Y, Zhou L, Huang Y, Zhang JW, Xiong SM, Chen SJ, Wang ZY, Chen Z, Chen GQ.
    Leukemia; 2000 Feb 21; 14(2):262-70. PubMed ID: 10673743
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: an useful salvage therapy.
    Huan SY, Yang CH, Chen YC.
    Leuk Lymphoma; 2000 Jul 21; 38(3-4):283-93. PubMed ID: 10830735
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Potentiation of arsenic trioxide-induced apoptosis by retinoic acid in retinoic acid sensitive and resistant HL-60 myeloid leukemia cells].
    Huang X.
    Chin Med J (Engl); 2000 Jun 21; 113(6):498-501. PubMed ID: 11775865
    [Abstract] [Full Text] [Related]

  • 10. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells.
    Chen GQ, Shi XG, Tang W, Xiong SM, Zhu J, Cai X, Han ZG, Ni JH, Shi GY, Jia PM, Liu MM, He KL, Niu C, Ma J, Zhang P, Zhang TD, Paul P, Naoe T, Kitamura K, Miller W, Waxman S, Wang ZY, de The H, Chen SJ, Chen Z.
    Blood; 1997 May 01; 89(9):3345-53. PubMed ID: 9129041
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Double effects of arsenic trioxide (As2O3) on acute promyelocytic leukemic cell line].
    Tang W, Chen G, Shi G.
    Zhonghua Yi Xue Za Zhi; 1997 Jul 01; 77(7):509-12. PubMed ID: 9772451
    [Abstract] [Full Text] [Related]

  • 13. Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells.
    Giannì M, Koken MH, Chelbi-Alix MK, Benoit G, Lanotte M, Chen Z, de Thé H.
    Blood; 1998 Jun 01; 91(11):4300-10. PubMed ID: 9596679
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient.
    Koken MH, Daniel MT, Gianni M, Zelent A, Licht J, Buzyn A, Minard P, Degos L, Varet B, de Thé H.
    Oncogene; 1999 Jan 28; 18(4):1113-8. PubMed ID: 10023688
    [Abstract] [Full Text] [Related]

  • 16. Treatment of acute promyelocytic leukemia with arsenic compounds: in vitro and in vivo studies.
    Chen Z, Chen GQ, Shen ZX, Chen SJ, Wang ZY.
    Semin Hematol; 2001 Jan 28; 38(1):26-36. PubMed ID: 11172537
    [Abstract] [Full Text] [Related]

  • 17. A novel differentiation-inducing therapy for acute promyelocytic leukemia with a combination of arsenic trioxide and GM-CSF.
    Muto A, Kizaki M, Kawamura C, Matsushita H, Fukuchi Y, Umezawa A, Yamada T, Hata J, Hozumi N, Yamato K, Ito M, Ueyama Y, Ikeda Y.
    Leukemia; 2001 Aug 28; 15(8):1176-84. PubMed ID: 11480559
    [Abstract] [Full Text] [Related]

  • 18. PIC-1/SUMO-1-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia.
    Sternsdorf T, Puccetti E, Jensen K, Hoelzer D, Will H, Ottmann OG, Ruthardt M.
    Mol Cell Biol; 1999 Jul 28; 19(7):5170-8. PubMed ID: 10373566
    [Abstract] [Full Text] [Related]

  • 19. Hypoxia-simulating agents and selective stimulation of arsenic trioxide-induced growth arrest and cell differentiation in acute promyelocytic leukemic cells.
    Yan H, Peng ZG, Wu YL, Jiang Y, Yu Y, Huang Y, Zhu YS, Zhao Q, Chen GQ.
    Haematologica; 2005 Dec 28; 90(12):1607-16. PubMed ID: 16330433
    [Abstract] [Full Text] [Related]

  • 20. Src family kinase inhibitor PP2 enhances differentiation of acute promyelocytic leukemia cell line induced by combination of all-trans-retinoic acid and arsenic trioxide.
    Jung YS, Cheong HJ, Kim SJ, Kim KH, Lee N, Park HS, Won JH.
    Leuk Res; 2014 Aug 28; 38(8):977-82. PubMed ID: 24953245
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.